Recruiting
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
ClinicalTrials.gov IDNCT06273072
PhasePHASE2
Enrollment100
SponsorJohns Hopkins University
Age18 Years and older
SexALL
Conditions studied
Asthma, Asthma Chronic, Overweight and Obesity
About this study
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
Interventions
- Drug: Metformin hydrochloride extended-release tablets — titrated to 2000 mg once daily
- Drug: Visually identical placebo Metformin hydrochloride extended-release tablets — placebo
Primary outcomes
- Number of completed telemedicine visits (Baseline to week 24)
- Adherence to study drug (Baseline to week 24)
- Retention rate (Baseline to week 24)
Eligibility information
Inclusion Criteria:
* Physician-diagnosed asthma on maintenance therapy
* Not well-controlled asthma (ACT score \<20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months)
* Overweight or obesity: Body mass index ≥25kg/m2
* Adult: Age ≥18
Exclusion Criteria:
* Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding
* Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months
* Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis
* Active smoking or former smoker with ≥20 pack-year smoking history
* Chronic kidney disease: estimated glomerular filtration rate ≤60 mL/min/1.73 m2
* Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man
* Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal or prior diagnosis of liver disease
* Anemia: hemoglobin \< 13 g/dl in males and hemoglobin \< 11 g/dl in females
* Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss
* Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes)
* Participation in any other clinical trial (observational studies are permitted)
Study locations
- Johns Hopkins University, Baltimore, Maryland 21224 United States
- Baylor College of Medicine, Houston, Texas 77030 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-09.